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Contributions of Gut Bacteria and
Diet to Drug Pharmacokinetics in the
Treatment of Parkinson’s Disease
Sebastiaan P. van Kessel and Sahar El Aidy*
Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute,
University of Groningen, Groningen, Netherlands
Parkinson’s disease is the second-most common neurodegenerative disorder worldwide.
Besides deciphering the mechanisms that underlie the etiology of the disease, it is
important to elucidate the factors that influence the efficacy of the treatment therapeutics.
Levodopa, which remains the golden treatment of the disease, is absorbed in the
proximal small intestine. A reduction in levodopa absorption, leads to reduction in striatal
dopamine levels and, in turn, an “off”-episode. In fact, motor fluctuations represent a
major problem during the progression of the disease and alteration between “on” (mobility
often with dyskinesia) and “off” (immobility, akinesia) episodes contribute to a decreased
quality of life. Dietary amino acids can interfere with the absorption of levodopa from the
gut lumen and its transport through the blood brain barrier. In addition, higher abundance
of specific gut bacteria that restrict levodopa absorption plays a significant role in motor
fluctuations in a subset of Parkinson’s disease patients. Here, we review the impact of
factors potentially interfering with levodopa absorption, focusing on levodopa transport,
diet, and gut bacterial interference with the bioavailability of levodopa.
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INTRODUCTION
Parkinson’s disease (PD) is the second-most common neurodegenerative disorder worldwide (1).
In 2015–2016, 6.1–6.2 million individuals were diagnosed with PD all over the globe (1, 2). The
prevalence of PD globally increases with age and peaks at 1.5% between 85 and 89 years of age
(2). During the progression of PD, patients encounter increasing severity of symptoms, which is
associated with rising costs for medical treatment, hospitalizations and nursing home care (3),
besides a significant decrease in the quality of life (3–6). The aggregation of α-synuclein in Lewy
bodies and loss of dopaminergic neurons (pars compacta) in the substantia nigra is the main
feature observed in PD patients (7). Although the exact factors contributing to the etiology of PD
are not well understood, the gut microbiota is likely to be a key contributor. This is evident from
the alteration in gut microbiota composition detected in fecal samples of PD patients compared
to healthy controls (HC) (8–12). Moreover, the production of short-chain fatty acids (SCFAs), the
main metabolic products produced by the large intestinal bacteria, is reduced in PD patients (12).
The latter has been shown to be involved in α-synuclein pathology in the gut in mouse models (13)
supporting the hypothesis that α-synuclein pathology starts in the enteric nervous system (14),
which synergizes with the finding of α-synuclein aggregates in colon tissue and appendix prior to
the onset of PD (15, 16). Equally important to elucidating the mechanisms involved in the cause
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of PD is to uncover the microbial and dietary interference
with the pharmacological treatment of the disease. Previous
studies have shown that Helicobacter pylori (HP) can interfere
with levodopa treatment and can bind to levodopa (3,4-
dihydroxyphenylalanine; L-DOPA) (17, 18). Recently, we showed
that bacteria can alter the levels of levodopa treatment in the
gut (19) resulting in quenching the availability of the drug
to be effective in the brain. This bacterial mediated reduction
in levodopa absorbed from the small intestine would lead to
reduction in striatal dopamine levels and an “off”-episode,
especially in patients with advanced stage PD, who have a
reduced capacity to store dopamine in the brain (20, 21). Besides,
fluctuating levodopa plasma levels could result in increased
pulsatile stimulation which is associated with dyskinesia (22).
The pharmacological treatment of PD and the gastrointestinal
(GI) dysfunction in PD have been extensively reviewed (23, 24),
mainly from a clinical perspective. This review focuses on the
impact of levodopa transport, gut bacterial degradation of PD
medication, and its impact on drug bioavailability. Furthermore,
we discuss the potential mediators that could lead to a vicious
circle where certain conditions (i.e., proton pump inhibitors and
gut motility) would favor the colonization of small-intestinal
bacteria, ultimately restricting the absorption of levodopa.
ADMINISTRATION ROUTES AND
TRANSPORT PROCESS OF LEVODOPA
The most common route for levodopa administration is
orally via immediate-release or extended-release formulations
of levodopa, where the latter might have potential benefits
over other levodopa formulations, reviewed in Mittur et al.
(25). Parenteral administration via subcutaneous injections are
impossible due to the low solubility of levodopa (26) and
continuous intravenous administration, although effective (27),
is impractical, as it requires large volumes of daily injections.
A promising alternative option to conventional levodopa
therapy for advanced PD patients with motor fluctuations and
dyskinesia is intestinal infusion of a levodopa/carbidopa gel via a
nasoduodenal tube (28) or via gastrojejunostomy (22).
When levodopa is administered orally, it is absorbed in
the proximal small intestine (29), where it has to be actively
transported from the lumen over the intestinal epithelial barrier
into the blood stream (30). To prevent peripheral and intestinal
levodopametabolism byDOPA decarboxylase (DDC), peripheral
DDC inhibitors, such as carbidopa, are co-administered with
levodopa. Levodopa (Figure 1) is a non-proteinogenic large
neutral amino acid (LNAA), and is therefore transported by
amino acid transporters in the GI-tract and at the blood brain
barrier (BBB) (Figure 2). The human body contains at least
11 different epithelial amino acid transport systems expressed
in the intestine, 10 of which are also expressed in the renal
epithelia, which was thoroughly reviewed before (31). Only two
amino acid transporters are expressed on the blood brain barrier
(BBB), LAT1 (SLC7A5) and SNAT5/11 (SLC38A5/11) (32). The
amino acid transporters, which are most likely responsible for the
transport of levodopa from the GI-tract to the blood and over the
BBB, based on in vitro/ex vivo studies, are discussed below and
summarized in Figure 2.
As a model for the BBB, a mouse brain endothelial cell line
(MBEC4), was tested for the expression of 4F2hc/LAT1
(SLC3A2/SLC7A5) and [3H]-levodopa transport was
evaluated in the presence of other amino acids (1:100
levodopa/amino acids). The study showed that tryptophan,
tyrosine, phenylalanine, isoleucine, leucine, histidine, and
2-amino-2-norbornane-carboxylic acid (BCH), which is used as
the defining synthetic amino acid for the L-system (consisting
of LAT1 to 4) (33), inhibited at least 80% of the [3H]-levodopa
uptake independent of Na+ (34). However, the potential
contribution of 4F2hc/LAT2 (SLC3A2/SLC7A8) or other
transporters were not addressed. Similar results were obtained in
Caco2 cells (35–38), renal proximal tubular epithelial cells (39),
and opossum kidney cells with either a high (HC) or a low (LC)
Na+ influx. Comparing the HC and LC cell lines indicated that
there was a minor contribution of Na+ dependent transport.
The authors concluded that 4F2hc/LAT2 (apparent from BCH
transport) and rBAT/b0,+ (SLC3A1/SLC7A9; apparent from the
uptake of the rBAT defining amino acid dimer, cystine) were
involved in levodopa transport (40). Although these studies
indicate which transporters are involved in levodopa transport
in the GI-tract, renal epithelia and the BBB, it remains unclear
which specific transporter is involved.
Studies using Xenopus laevis oocytes, an ideal single-cell
expression system for transporters due to its relatively large
size and low background activity (41), showed that 4F2hc/LAT1
(from rat C6 glioma cells) (42), 4Fhc/LAT2 (43), rBAT/b0,+ (from
rabbit intestine and human) (43, 44), and TAT1 (SLC16A10)
(from rat intestine) (45) are independently responsible for
levodopa transport. Only substrates with both positive and
negative charges at the α-carbon (the relative positive and
negative charges are from the amine-group and carboxyl-group
from levodopa, respectively, Figure 1) are being able to be
transported via 4F2hc/LAT1 (42). Importantly levodopa analogs
(m-O-methylDOPA, α-methylphenylalanine, α-methyltyrosine,
α-methylDOPA), gabapentin [γ-aminobutyric acid (GABA)
analog], melphalan (a chemotherapeutic agent), and thyroid
hormones (T3, triiodothyronine and T4, thyroxine) were able
to inhibit transport of L-[14C]-phenylalanine, and thus levodopa
(42), showing the broad range of potential levodopa transport
inhibitors. In fact, anti-thyroid treatment in a 70-year-old male
subject with PD on levodopa treatment had a beneficial effect
on the exaggerated Parkinsonian tremor (46). The authors could
not explain why the Parkinsonian tremor was aggravated by the
presence of hyperthyroidism. However, a plausible explanation,
which was not discussed, is the interference of exaggerated
thyroid hormone levels with levodopa uptake in the brain. Thus,
hyperthyroidism, which is prevalent at higher age, should be
considered in PD patients (46).
In X. laevis oocytes expressing TAT1, around 80% of L-[14C]-
tryptophan uptake was inhibited by tyrosine and tryptophan
and about 40% was inhibited by phenylalanine, levodopa,
and m-O-methylDOPA, indicating that TAT1 is an aromatic
amino acid transporter partly responsible for levodopa uptake.
Using N-acetylated amino acids, the authors concluded that
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FIGURE 1 | Human and bacterial levodopa metabolism. Levodopa is produced by hydroxylation of the meta-position of the phenyl-ring from tyrosine by TH (tyrosine
hydroxylase) using molecular oxygen. Sequentially levodopa can be decarboxylated to the active neurotransmitter dopamine by the AADC [aromatic amino acid
decarboxylase, also known as DDC (DOPA decarboxylase)], or can be methylated by COMT (catechol-O-methyltransferase). Bacterial TDC (tyrosine decarboxylase)
can decarboxylate (m-)tyrosine to (m-)tyramine but also levodopa to dopamine. Furthermore, bacteria can dehydroxylate the para-hydroxyl group of either levodopa or
dopamine and can sequentially deaminate the dehydroxylated products.
the α-carboxyl group (Figure 1) is essential for substrate
recognition by TAT1. Furthermore, it was shown that TAT1 is
mainly expressed throughout in the rat GI-tract and in the liver,
in particular, on the basolateral side of rat small intestine (45)
(Figure 2). Using trans-well culturing and everted murine jejunal
sacs, the authors concluded that 4F2hc/LAT2 (LAT1 was not
tested) and TAT1 are responsible for the basolateral transport
of levodopa (30). In contrast to 4F2hc/LAT1, 4F2hc/LAT2,
and TAT1, which are expressed basolaterally, rBAT/b0,+AT is
expressed apically and thus is mainly responsible for levodopa
absorption from the intestinal lumen. Further characterization
of rBAT/b0,+AT showed that the common co-administered
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FIGURE 2 | Bacterial degradation and dietary components restrict levodopa
transport. Levodopa is taken up in the small intestine by the apical transporter
rBAT/b0,+AT, and is sequentially is transported over the basolateral membrane
by 4F2hc/LAT2 and TAT1. The uptake from the lumen can be compromised by
LNAAs apically and by LNAAs and AAAs basolaterally. Bacterial degradation
can interfere with levodopa before it is transported and elevate levels of
dopamine in the lumen. Higher levels of luminal dopamine could affect the gut
motility, which, in turn, could result in a state of small intestinal bacterial
overgrowth, creating a vicious circle. The fraction of levodopa that ends up in
the blood has to be transported over the BBB via 4F2hc/LAT1, which can be
compromised by high levels of thyroid hormones (T3/T4), or LNAA. Serine left
over from a late proteic meal, can trans-stimulate 4F2hc/LAT2 inducing higher
efflux of levodopa in the circulation. Finally, the remaining levodopa will be
converted to dopamine in the brain by DDC, to compensate the loss of striatal
dopamine levels in PD patients.
inhibiters of peripheral levodopa degradation, carbidopa,
benserazide (decarboxylase inhibitors) and entacapone
[catechol-O-methyltransferase (COMT) inhibitor] were unable
to compete with rBAT/b0,+AT mediated levodopa transport,
indicating that other transporters/mechanisms are involved
in the uptake of peripheral levodopa metabolism inhibitors
(30). The transport of levodopa via other apical transporters,
PAT1, SIT1/ACE2, ASCT2, and B0AT1/ACE2 (the main other
natural amino acid transporter), expressed in X. laevis oocytes
was investigated and showed that none of them was able to
transport levodopa, indicating that rBAT/b0,+AT is the main
apical levodopa transporter (30) (Figure 2).
EFFECT OF DIET AND AGE ON THE
BIOAVAILABILITY OF LEVODOPA
Early studies in vivo, using radiolabeled levodopa ([14C]-
levodopa) showed that ∼90% of the total radioactivity is
transported into the circulatory system as measured in urine
samples after 48 h (47–49). Notably, only ∼13% of the total
radioactivity in blood plasma after the first hour was from intact
levodopa, and decreased further overtime. When carbidopa was
used in combination with levodopa the intact levodopa after
the first hour increased to ∼43% (47). These studies indicate
that less than half of the administered levodopa would reach
the brain and that approximately 10% of the total levodopa
radioactivity is not absorbed and could end up in fecal samples.
Moreover, levels of unabsorbed levodopa increase over age. For
example, a 10-fold increase (24.6–35.4% vs. 2.7–3.5% recovered
radioactivity) in levels of levodopa (including its metabolites)
were detected in fecal samples of old rats (0.5–2 years old)
when compared with their younger counterparts (5–15 weeks
old) after oral administration of [14C]-levodopa (50). This was
not related to an increased fecal excretion or decreased jejunal
blood flow, suggesting that there is impaired uptake at older
age (50). When levels of levodopa were measured over time in
plasma (AUC), older animals (1–2 years) had a higher AUC
and a longer half-life (T1/2) of systemic levodopa compared
to younger animals (9–26 weeks), suggesting an age-dependent
slower total body clearance of levodopa (50). Furthermore the
study showed that the intestinal metabolism (mainly by DDC),
which prevents levodopa to reach the brain and decreases over
age, contributes the most to the increased systemic availability of
levodopa at older age (50). The decreased clearance of levodopa
at higher age in rats is in agreement with a study performed
in healthy human subjects, who were administered levodopa
without DDC inhibitors (51). Coherently, a higher AUC and
systemic levodopa bioavailability (AUCoral/AUCintravenous) for
levodopa was observed in elderly (71.0 years n= 9) compared to
young subjects (21.8 years n = 8). Administration of carbidopa
diminished the differences in systemic levodopa bioavailability
between the two groups, while a higher AUC was still observed
in the elderly group. This suggests a lower systemic clearance
at higher age because carbidopa abolished the age differences
in systemic levodopa bioavailability (51). In PD patients, age
correlated significantly with higher levodopa (supplied with
DDC inhibitor) AUC and decrease in clearance (52, 53).
However, the high scatter in the correlation (r2 = 0.15–0.24)
from that study implies that other factors besides age contribute
to the variation among PD patients in the pharmacokinetics of
levodopa (52).
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Indeed, impaired uptake of [14C]-levodopa into the brain
was observed when rats were supplied intravenously with the
amino acids, phenylalanine, tryptophan, and to a lesser extent
histidine (54). The same effects were reported in humans, for
example, a clinical study showed that PD patients (n = 9),
who received levodopa/carbidopa intravenously directly after
a protein rich meal (containing LNAAs) or administration
of LNAAs, had increased Parkinsonian symptoms. Similarly,
when levodopa/carbidopa was taken orally, levodopa absorption
from the intestine was delayed after a protein-rich meal
(55). When levodopa/benzerazide (another DDC inhibitor) was
infused intraduodenally, motor functions decreased after protein
ingestion (56), indicating fluctuation in levodopa uptake in
the brain. Nonetheless no decrease in levodopa absorption
was observed (56) suggesting that the variability in plasma
LNAAs, absorbed from the intestine, could be responsible for
the fluctuating levodopa uptake in the brain (57). The authors
concluded that during ingestion of regular (hospital) diets,
10% of the levodopa brain uptake variability is explained by
LNAAs in plasma and the other 90% by levodopa plasma
levels (57). These hospital diets contained 2–3.7-fold less
LNAAs compared to other human studies [615 ± 105µM (57)
compared to 1,235–1,973µM (55), 1,615–2,012µM (58), 1,624–
2,292µM (56)] indicating that high LNAA levels do interfere
with levodopa absorption in PD patients but are not solely
responsible for the “on”–“off” fluctuations observed in PD
patients. Notably, cationic (lysine) or small (glycine) amino
acids had no effect on the “on”–“off” fluctuations (55). Using
regional jejunal perfusion of levodopa in healthy human subjects
it was shown that the LNAA L-leucine interfered with the
levodopa absorption from small intestine (59), at least at high
concentrations. This finding supports the involvement of the
L-transport system for levodopa transport (as described above)
from the intestine to the blood circulation, and, ultimately, to the
brain (Figure 2).
In vitro data and clinical investigations on the effect of
amino acids on the transport and bioavailability of levodopa
clearly indicate that amino acids can interfere with the uptake
of levodopa from the lumen or the systemic circulation.
Therefore, low protein diets (LPD) or protein redistribution
diets (PDR), where all dietary protein is ingested only during
the evening meal, are proposed for PD patients with motor
fluctuations (60). Refined physiologically based pharmacokinetic
(PBPK) modeling for GI absorption (WB-ACAT, Whole Body—
Advanced Compartmental Absorption and Transit Model)
combined with dynamic flux balance analysis (which measures
the flow of metabolites through a metabolic network) on
an epithelial cell (sIEC) model for small intestine segmented
into 7 parts (WB-ACAT-sIEC), was used to investigate the
spatiotemporal relationship between amino acids and levodopa
uptake kinetics (61). Simulation of levodopa absorption during
an aproteic or proteic meal showed that that dietary intervention
would be beneficial for PD patients with Hoehn and Yahr scale
3/4 (HY3/4; HY describes the disease progression from (mild
= 1) to severe = 5) (61). These findings are in agreement with
the guidelines for PD treatment, where dietary interventions
are proposed for advanced PD patients (20, 21). Comparing
a LPD (in silico administration of 0.8 g/kg amino acids
together with 200mg levodopa) vs. a PRD (assuming a high
fraction of amino acids present in the systemic circulation
before the morning levodopa dose) in the WB-ACAT-sIEC
model showed a cumulative increase in AUC of levodopa
during PRD. Furthermore, the AUC after a morning levodopa
dose was higher (11.23%) during PRD than during a fasting
state, which was attributed to a higher influx of residual
systemic LNAA from the last protein meal taken the evening
before levodopa administration. This higher influx through the
basolateral antiporter induced a higher eﬄux of levodopa (trans-
stimulation) into the circulation (61) (Figure 2). Although PRD
could provide short-term benefits as evident by the reported
response rates of >80% (60), it might not provide a long-term
solution as it is undesired by patients and is an imbalanced diet
(20, 21) that results in weight loss among patients (60). Extending
theWB-ACAT-sIECmodel with kidney and brain compartments
and setting the objective function (a desired outcome) for
optimizing levodopa transport across the BBB revealed that
threonine, serine and asparagine resulted in the highest brain
bioavailability of levodopa. This led the authors to propose that
a serine-rich meal taken after the last levodopa treatment could
be beneficial for the levodopa bioavailability (61). Nonetheless,
sensitivity analyses (i.e., the variable that contributes most to
the dependent outcome) showed that intestinal loss of levodopa
was the most influential factor on levodopa bioavailability (61).
Indeed, changes in the levels of levodopa in the small intestine
are affected by gut bacterial interference (17, 19), as discussed in
the next section.
GUT BACTERIAL INTERFERENCE WITH
LEVODOPA BIOAVAILABILITY
Levodopa is a non-proteinogenic amino acid produced by
the hydroxylation at the meta-position of the phenyl ring of
tyrosine. Subsequently, levodopa can be converted to dopamine
by DDC or to m-O-methylDOPA by COMT methylating of
the m-hydroxyl group in the human body (Figure 1). The
microbiota also poses enzymes able to perform similar or
additional reactions, which metabolize levodopa. In the early
70s, a study, comparing the metabolic profile of germ-free and
conventional rats, showed production ofm-hydroxyphenylacetic
acid and m-hydroxyphenylpropionic acid (Figure 1) only in
conventional rats when fed with levodopa, suggesting that a
bacterial dehydroxylation reaction was involved (62). When rat
caecal content was incubated with levodopa or dopamine for 6
days also m-tyramine was found, confirming earlier findings in
humans (63). Metabolites were detected over periods of 3 days in
the urine indicating that the detected metabolites could originate
from in the large intestine, which is supported by the caecal
incubations (62). Since the main site of levodopa absorption
is the proximal small intestine, it is unlikely that bacterial
metabolism of levodopa in the large intestine would affect the
drug bioavailability. Therefore, it is crucial to investigate potential
bacterial interference with levodopa treatment in the proximal
small intestine.
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Recently, we showed that gut bacteria harboring tyrosine
decarboxylases (TDC), mainly enterococci, can effectively
decarboxylate levodopa to dopamine in the small intestine of
rat. The study concluded that the natural variation of the tdc-
gene negatively correlated with the levodopa levels in the blood
of rats and positively correlated with the daily dose requirement
of levodopa in PD patients (19). High abundance of these
bacteria in PD patients, which could be caused by small intestinal
overgrowth (SIBO), could have implications on the absorption
of levodopa from the small intestine (Figure 2). To assess the
contribution of those bacteria to the bioavailability of levodopa in
PD patients, we are currently performing further clinical studies.
In healthy conditions, SIBO is prevented by the ileocecal
valve, pancreatic enzyme activity, gut motility and gastric acid
(64). Importantly in PD patients, the prevalence of gut motility
dysfunction (constipation) and proton pump inhibitor (PPI)
usage is relatively high (77.1 and 39.6% respectively, n = 39)
(65) and is associated with SIBO (66). In patients (n = 200)
with gastroesophageal reflux disease using PPIs, varying from 2
months to 7 years, SIBO was detected in 50% of the cases and was
significantly higher than in healthy controls (n= 50) (66). Studies
looking at the alteration of the microbiota in subjects using
PPIs showed increased levels of Bacilli (including Lactobacillus,
Staphylococcus, and Enterococcus) in fecal samples (67, 68). In
duodenal samples, SIBO was also observed in 56% of patients on
PPIs (n = 25) and included mainly genera from the Bacilli class
(69). Bacterial species from the Bacilli class are of importance
as they harbor TDCs, which are able to interfere with levodopa
levels (19). When SIBO is eradicated in PD patients with
Helicobacter pylori infection using rifaximin, a common non-
absorbable antibiotic used to treat SIBO (70), motor fluctuations
were improved as apparent from the significant decreased
delayed “on” episodes/day and daily “off” time, although no
significant increase in levodopa pharmacokinetics was observed
(71). The underlying explanation of improvedmotor fluctuations
following SIBO eradication remains to be elucidated. However, a
plausible explanation is that eradication of bacterial degradation
of levodopa in the small intestine altered levels of the levodopa
metabolite, dopamine, in the small intestinal lumen (19), and/or
eliminated SIBO-induced small intestinal inflammation (71).
In 2001, investigators observed a clinical improvement in
PD patients after treatment with antibiotics used to eradicate
Helicobacter pylori in two almost identical reports. When
HP-infections were treated, the mean AUC of levodopa in
the blood significantly increased by ∼1.2-fold. A UPDRS-
III motor examination showed indeed a significant decrease
in motor score (72, 73). A follow-up study confirmed these
findings in a larger cohort (n = 17) and showed that either
2 weeks or 3 months after HP eradication, PD patients had
higher levodopa blood levels (AUC) and lower UPDRS-III
motor scores compared to before the eradication (18). Other
studies did not find a significant difference in pharmacokinetics
(74) or LEDD (levodopa equivalent daily dose) (75, 76) of
levodopa between PD patients tested positive or negative for
HP infection. In addition, no motor improvement (UPDSR-
III) was found after HP eradication in 34 patients (75). Despite
the discrepancy among studies, Helicobacter pylori might still
play a significant role in drug absorption. The mechanism of
Helicobacter pylori affecting the levodopa absorption is unclear,
one possible explanation for altered drug absorption might
be the gastric acidity, which is altered by Helicobacter pylori
infection and therefore interferes with drug pharmacokinetics
of levodopa, delavirdine, and thyroxine (77). Interestingly, an in
vitro study showed that adhesins exposed on the outer membrane
of Helicobacter pylori might bind to levodopa and therefore
might contribute to the lower pharmacokinetics in Helicobacter
pylori infected PD patients (17). No follow-up studies were
published and it remains to be elucidated which adhesin(s) are
responsible for binding levodopa. Besides, whether the antibiotic
cocktail used to treatHelicobacter pylori infections (1,000/500mg
amoxicillin/clarithromycin) could also eradicate other bacterial
species in the small intestine, which might interfere with the
availability of levodopa, and thus could be the actual reason
behind the observed increase in blood levels of levodopa, was
not investigated.
EFFECT OF DOPAMINE AND DOPAMINE
AGONISTS ON GUT MOTILITY
Bacterial species from the Bacilli class, especially enterococci, are
able to produce luminal dopamine (19). Importantly, dopamine
and their agonists have been shown to affect the gut motility
(discussed below), which could potentially favor the colonization
of levodopa decarboxylating bacteria (19) (Figure 2). In addition,
the dopamine agonists, which are usually used in combination
with levodopa treatment, could have a similar effect on
influencing gut motility to favor colonization of specific bacterial
species. Therefore, studies investigating the effects of dopamine
on gut motility of rodents, dogs, and humans were reviewed, with
a complete overview in Table 1.
Using electrical field stimulation (EFS) on longitudinal muscle
strips of guinea pig ileum in organ baths, dopamine (1–100µM)
and bromocriptine (0.15–15µM), a dopamine agonist used in PD
treatment, inhibited the cholinergic twitch up to∼46 and∼82%,
respectively. Neither dopamine antagonists, metoclopramide
nor pimozide prevented the observed inhibition by dopamine
or bromocriptine. When using the α-adrenoceptor antagonist,
phentolamine, only the observed inhibition of dopamine but
not of bromocriptine was rescued, indicating that dopamine
acts through the α-adrenoceptors (78). The same conclusions
on the inhibitory effect of dopamine were shown in an almost
identical study using ileum of guinea pig (79). Notably, tyramine,
a product of bacterial TDC, resulted in similar inhibitions of
cholinergic twitch (79). Dopamine, bromocriptine, and to a
lesser extent tyramine, were also able to relax methacholine-
contracted jejunal tissues from guinea pig (80). In rats, dopamine
initiated directly a short longitudinal contraction followed by
relaxation within 5min in the duodenum and jejunum. However,
in the ileum, only relaxations were observed (81). In addition,
dopamine had also an inhibitory effect on the spontaneous
contractions of longitudinal muscle strips from rat distal colon
(82). Themotility of mouse longitudinal fixed ileum (83), circular
muscle strips of colon (84) and longitudinal fixed colon (85)



































TABLE 1 | Studies investigating the effects of dopamine and dopamine agonists on gut motility in rodents, dogs and humans.




























































Inhibition of motility by all compounds
tested. Potentially through α-adrenergic
receptors. The potency (pA2*) of
metoclopramide and sulpiride was not
different between dopamine or
norepinephrine, indicating an α-adrenergic
inhibition, confirmed by tolazoline
Lucchelli
et al. (80)






























Relaxation of tissue of all tested compounds
(Reserpine, had no effect on DA induced
relaxation, and a minor effect on the others).
Slight inhibition of phentolamine
(α-adrenoceptor antagonist) and propranolol
(ß-adrenoceptor antagonist). Inconclusive
which receptor is involved
Kirschstein
et al. (81)











None All tested Contraction and relaxation observed in
duodenum and jejunum, relaxation only
observed in Ileum. Contraction inhibition by
SCH-23390 and raclopride, relaxation
inhibition by propranolol and prazosin
Zhang
et al. (82)
Rat Organ bath Distal colon;
longitudinal
strips
Inhibitory Dopamine (3–30) SCH-23390 (10),
Supiride (10)
Not tested TTX (1) SCH-23390 Dopamine inhibited the spontaneous
contractions with EC50=8.3µM and was
not affected by TTX. The inhibitory affect was
affected only by D1R antagonist SCH-23390
Zizzo et al.
(83)









































Contractibility was inhibited by dopamine
and SKF-38933 (D1R agonist), at high
concentrations adrenoceptor antagonists
(SR-59230, phentolamine, yohimbine)
slightly prevented the inhibitory effect of
dopamine. D2 antagonists sulpiride and
domperidone had little effect on the
inhibitory effect of dopamine, except when
combined with SCH-23390 (D1R antagonist)
which induced a stronger effect then
SCH-23390 alone. Suggesting a synergic




















































































TABLE 1 | Continued

























































Relaxation induced by DA via a D2-like
receptors; Not dependent on NO or P2Y1
receptors; Not affected by adrenergic
antagonists; not dependent on enteric
neuronal action potential or on modulation of
neurotransmitter release; SCH-23390
increased basal tone and the amplitude of
the spontaneous contractions; Relaxation of
bromocriptine is inhibited by domperidone
Walker
et al. (85)











Not tested None SCH-
23390/sulpiride
Dopamine was only tested on WT distal
colon and showed a inhibitory effect (EC50
= 4.5µM), which was slightly abolished by
SCH-23390/sulpiride mixture (EC50 =















None None None NA Decreased the duration of the migrating
motor complex episodes in the small
intestine 1 h before a meal compared to
controls (from 9.4 to 3.4 h and 7.8 to 2.4 h in
duodenum and jejunum), although
































Dopamine had a inhibitory effect on the
ascending and transverse colon and a
inducing effect on the descending colon
MMCs. Bromocriptine had a inducing effect
in the whole colon MMCs; Potentially





























Dopamine induced phase-III like MMCs in
the duodenum, similar to spontaneous
phase-III MMCs, although a slight longer
period of complete inhibition after phase-III
MMCs; Domperidon and sulpiride prevented




















































































TABLE 1 | Continued










































None None Domperidon Dopamine induced phase-III like MMCs
during fed state in the small intestine, which
was inhibited by domperidone, and
decreased the motility of the stomach. After
the phase-III MMCs a short period of













None None None NA Dopamine reduced the AUC(60min) of
paracetamol significantly, associated with a
delayed gastric emptying; OCT time was
significantly longer then controls indicating a



















1.5 cm apart for
stomach and











None None None NA Decreased number of contractions in the
gastric antrum (only significant during
fasting) and induced phase III motor activity
in the duodenum (only significant during
feeding)
*pA2, the concentration that produces a 2-fold shift in the agonist concentration-response curve; Dopaminergic antagonists: SCH-23390, D1 receptor antagonist; Domperidone, Haloperidol, Metoclopramide, Pimozide, Raclopride,
Sulpiride, D2 receptor antagonist; cis-flupentixol, D1 and D2 receptor antagonist; Adrenergic antagonists: Tolazoline, Phentolamine, Prazosin, α1 adrenergic receptor antagonist; Yohimbine, α2 adrenergic receptor antagonist;
Propranolol, ß adrenergic receptor antagonist; SR-59230A, β3-adrenoceptor antagonist; Other antagonists and inhibitors: Apamin, SKCa channel blocker; Atropine, Muscarinic receptor blocker; Carbachol, Cholinergic agonist;
Charybdotoxin, IKCa-BkCa channel blocker; DDA, Adenylyl cyclase inhibitor; DMPX, Adenosine A2 receptor antagonist; DPCPX, Adenosine A1 receptor antagonist; Iberiotoxin, BKCa channel blocker; L-NAME, NO synthase inhibitor;
Methysergide, 5-HT receptor antagonist; MRS-1220, Adenosine A3 receptor antagonist; MRS-2179, Purinergic P2Y1 receptor antagonist; Reserpine, VMAT inhibitor; SNX-482, P/Q-type Ca2+ channel blocker; TTX, Na+voltage-gated
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were all inhibited by dopamine and in the latter study also
by bromocriptine, attributed to dopaminergic and/or adrenergic
receptors. In dogs, the gut motility of the small intestine (86) and
the colon (87) was monitored in vivo using implanted electrodes.
Injection of dopamine (10 µg/kg) intracerebroventricularly 1 h
before a meal decreased the duration of the migrating motor
complex (MMC; intestinal motility pattern of the interdigestive
state) episodes in the small intestine compared to controls,
although this effect was not observed when dopamine was
injected intravenously (100 µg/kg) (86). In the colon, a similar
inhibition was observed, although with a 10 times higher
concentration of dopamine (1 mg/kg/h) injected intravenously
(87). Importantly, bromocriptine had an opposite effect, where
it induced the colon motility instead (87). In fasted human
subjects, intravenous administration of dopamine (75 µg/kg in
15min) induced phase-III like MMCs (last phase in the MMC
cycle which consists of strong contractions to completely occlude
the lumen) in the duodenum (88), which is in contrast to
the previous studies in rodents (organ bath experiments) and
dogs. The MMCs were similar to spontaneous phase-III MMCs,
although with a slight longer period of complete inhibition after
phase-III MMCs (88). Similar results were found in terminally
ill patients (91). A follow up study in humans during fed
state showed that dopamine disrupted the fed state MMCs and
induced phase-III like MMCs, followed by a short period of
complete quiescence (phase-I like MMCs), which was inhibited
by the dopamine receptor D2 blocker (DRD2) domperidone,
suggesting the involvement of peripheral D2 receptors (89).
Lastly, when the gut motility was investigated using orocaecal
transit time (OCT) and paracetamol pharmacokinetics as gastric
emptying marker during intravenous injection of dopamine (90),
a reduction in the AUCt=60min of paracetamol was observed. This
suggests that dopamine causes delayed OCT time, which could
be due to delayed gastric emptying and a decrease in gut motility
(90). Functional studies investigating the dopamine receptors in
the GI-tract of mouse showed that the dopamine receptor D2
(Drd2) is important for gut motility. Mice lacking Drd2, but not
Drd3, receptor showed an increased gut transit time compared
to the controls (92) suggesting that endogenous dopamine has
an inhibitory effect on intestinal motility (92). The findings
confirm the earlier organ bath experiments with rodent tissue. In
summary, these studies (Table 1) show that in rodents and dogs
the GI motility is inhibited by dopamine through dopaminergic
and adrenergic receptors.
In contrast, in humans, dopamine seems to inhibit stomach
motility and induce phase-III like MMCs followed by a short
time of quiescence through dopaminergic receptors. A potential
explanation of the discrepancy among the human and the animal
studies might be the experimental setup. In rodents, dissected
intestinal parts were placed in an organ bath ex vivo and in
dogs electrodes were implanted on the basal side of segments of
the GI-tract (86, 87). In contrast, in human studies, nasojejunal
luminal-tubes consisting of catheters with side openings were
fluoroscopically placed in the GI-tract and perfused with 0.2–1.59
mL/min water (88, 89, 91). The latter might induce an altered
gut motility per se in a non-physiological manner. More studies
should be conducted to test the effects of dopamine on the gut
motility in humans, and especially in PD patients, who might
already have an altered gut motility (4).
CONCLUSIONS AND FUTURE
PERSPECTIVES
The “on”/“off” motor fluctuations in PD patients are highly
dependent on the pharmacological treatment and factors
contributing to its efficacy. Dietary amino acids and gut
bacterial interference with levodopa treatment can contribute
to the reduction of levodopa dosage absorbed in the small
intestine, thereby restrict the effectiveness of the treatment.
Especially luminal dopamine, which is produced by gut bacterial
degradation of levodopa and is affecting the gut motility, would
enhance the overgrowth of these bacteria in the small intestine
and result in a vicious circle that enhances SIBO. The effect of
dopamine on (small) intestinal motility, urges the investigation
of the effect luminal dopamine and dopamine agonists on the gut
motility of PD patients. Finally, it is crucial to accurately measure
levels of SIBO in PD patients, especially in those who administer
PPIs, and to diagnose other possible underlying diseases, such as
hyperthyroidism. These precautions will help reduce the factors
contributing to compromised levodopa bioavailability and the
unwarranted side effects that result from increased frequency of
dosage treatment regimen.
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